Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 2.6/5
BeiGene

BeiGene (6160 HK)

392
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
bullishBeiGene
17 Feb 2025 04:21

Quiddity Leaderboard Hang Seng Index: Healthcare Is Still the Most Under-Represented Industry Group

The Hang Seng Index February 2025 index review results will be confirmed on Friday this week (21st). This would be a good time to revisit this...

Share
14 Dec 2022 01:38

China ADRs Delisting - Friday Could Be Judgment Day for over US$800bn Mcap of Stocks

PCAOB officials concluded their Hong Kong visit last month and PCAOB is due to announce its annual judgment on whether it had adequate access to US...

Logo
1.1k Views
Share
20 Jul 2025 06:32

Quiddity Leaderboard Hang Seng Index Sep25: BeOne, TME, and Pop Mart Among Our Top Picks

We have picked 10 names with high likelihood of Hang Seng Index addition in September 2025 and we expect these names to outperform the index over...

Share
20 Jul 2025 02:15

A-H Premium Weekly (Jul 18th): Livzon Pharmaceutical, Cosco Shipping Development, Beigene

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Livzon Pharmaceutical, Cosco Shipping Development, Beigene,...

Logo
264 Views
Share
bullishBeiGene
17 Dec 2024 02:21

HK CEO & Director Dealings (17th Dec 2024): BeiGene, China Wantian, Super Hi Int'l/Haidilao

The data in this insight is collated from the "shareholding disclosure" link on the HKEx website.  These insights also flag those companies where...

Logo
322 Views
Share
x